Question Bank › Demand pull is outrunning the plan for one still

Demand pull is outrunning the plan for one still-small offering, and the company is visibly re-pointing…

Demand pull is outrunning the plan for one still-small offering, and the company is visibly re-pointing itself at it

Calls Tested
487
Answered YES
7
Hit Rate
1.4%
rare by design

Alkermes plc (ALKS) — this company's answers

NO on the Q3 2018 call 2018-10-23 C
The model's full reasoning — Q3 2018 call → NO我们根据提供的财报电话会议记录,寻找一个具体的、可识别的产品/服务/计划,其中管理层明确表示客户反应超出预期,并且公司正在采取具体措施扩大对该产品的投入,且该产品目前仍占公司整体业务的一小部分。 在记录中,管理层提到了几个产品:VIVITROL、ARISTADA(包括ARISTADA INITIO)、ALKS 5461、ALKS 3831、BIIB098、ALKS 4230等。 关于ARISTADA INITIO,Jim Robinson说:“Following the launch of ARISTADA INITIO, we have seen an acceleration in the sequential growth of the two-month dose, which grew 26% and accounted for 15% of ARISTADA's volume in the third quarter.” 这表示客户反应良好,但这是否“超出准备”?管理层说“We are encouraged by our customers' positive response thus far”,但并未明确说超出预期。此外,公司正在扩大销售队伍:“During the fourth quarter, we will further expand our field and hospital-based sales force by approximately 50 sales representatives based on the opportunities we are identifying and the encouraging trends that we are seeing.” 这表示公司正在响应,但这是否是“现在”正在进行的?他们说“will further expand”在第四季度,但电话会议是在10月23日,第四季度已经开始,所以可能正在发生。但需要确认是否明确说“超出准备”。管理层没有明确说“超出我们准备的”,只是说“encouraging trends”。另外,ARISTADA整体是公司的主要产品之一,但ARISTADA INITIO是新产品,可能算小部分。 关于VIVITROL,管理层说“we continue to see strong growth”,但这是主要业务,不是小部分。 关于ALKS 5461,尚未获批,没有当前客户反应。 关于ALKS 3831,尚未获批。 关于BIIB098,尚未获批。 关于ALKS 4230,处于早期临床,没有客户反应。 因此,最接近的是ARISTADA INITIO,但管理层没有明确说“客户反应超出准备”,只是说“encouraging”。另外,公司正在扩大销售队伍,但这是针对ARISTADA整体,还是专门针对INITIO?他们说“based on the opportunities we are identifying and the encouraging trends that we are seeing”,可能包括INITIO。但需要更明确的表述。 再仔细看,Jim Robinson说:“We are encouraged by our customers' positive response thus far, especially key hospitals and health plans, as evidenced by the addition of both ARISTADA and ARISTADA INITIO to formularies at more than 30 hospitals during the quarter. To put that into context, this increases the number of hospital formularies including both products by nearly 30%.” 这表示客户反应良好,但未说超出准备。另外,公司正在提供样品:“we are strategically providing samples to hospitals and physicians in order to foster more experience using INITIO.” 这算扩大投入吗?可能。 但问题要求“customer response is running ahead of what the company had prepared for”,即明确表示实际需求超过公司准备。这里没有明确说“超出我们准备的”,只是说“encouraging”。另外,公司扩大销售队伍是“will further expand”在第四季度,但电话会议时第四季度已经开始,所以可能正在发生,但表述是未来时。 此外,公司还提到“we will further expand our field and hospital-based sales force by approximately 50 sales representatives”,这可能是针对ARISTADA整体,而非专门针对INITIO。 另一个候选是ALKS 4230,但那是临床,没有客户。 因此,我认为没有明确满足两个条件。管理层没有明确说“需求超出准备”,也没有明确说“正在采取具体步骤扩大”针对同一产品,且该产品是小的。 所以答案应为NO。

← Back to the full ALKS analysis

Show the exact prompt the model was given
Using ONLY the supplied earnings call transcript and no outside information: On this call, does management describe ONE identifiable offering or initiative of the company — a product, service, program, format, capability, market, or line of business that is still a clearly smaller part of the company's overall results today — for which BOTH of the following are conveyed in management's own words as a present-tense reality: (1) CUSTOMER RESPONSE IS RUNNING AHEAD OF WHAT THE COMPANY HAD PREPARED FOR. Management indicates that real, current uptake of this offering — actual orders, sign-ups, bookings, volumes, enrollments, deployments, sell-through, or usage happening now — is stronger, faster, or broader than the company had planned, staffed, stocked, built, or budgeted for. This may come through in many forms fitting the business: demand exceeding what was allocated to it, the offering selling out or running ahead of supply or capacity set aside for it, adoption outpacing the rollout schedule, interest arriving from more customers or channels than the plan assumed, or management plainly saying the response has exceeded what they anticipated when they sized the effort. What matters is a described gap between the customer response actually arriving and the scale the company had prepared — grounded in current activity, not in hopes or projections. (2) THE COMPANY IS RESPONDING RIGHT NOW BY PUTTING MORE OF ITSELF BEHIND IT. Management describes concrete steps already underway — not merely planned — to enlarge the company's commitment to this same offering: adding capacity, production, inventory, locations, staff, or investment dedicated to it; accelerating or broadening its rollout; reallocating people, capital, or capacity toward it from elsewhere; or moving up timelines because of the response. The response should be described as in motion in the current period. Answer YES only when both halves are present about the SAME identifiable offering, and that offering is still small relative to the company's total business, so the reported results reflect only the beginning of its contribution. Answer NO if the strong uptake described is simply the company's main established business performing well; NO if the offering's momentum is described only through pipeline, interest, or expectations rather than current real uptake; NO if the company is not described as taking concrete steps now to expand behind it; NO if the expansion steps are only under consideration or scheduled for the future; NO if the demand-ahead-of-plan framing refers only to a quarterly financial beat rather than to a specific offering outrunning the company's preparation for it; NO if the initiative is being expanded defensively to offset weakness elsewhere rather than in response to its own demand; and NO if the dynamic appears only in an analyst's question that management does not itself affirm. Use only the supplied transcript. Answer only YES or NO.

Companies that answered YES

TickerCompanyCallDateCall grade
HCKT The Hackett Group, Inc. Q1 2024 2024-05-08 C
ROCK Gibraltar Industries, Inc. Q1 2024 2024-05-01 B+
GIII G-III Apparel Group, Ltd. Q4 2024 2024-03-14 C
PRPH ProPhase Labs, Inc. Q1 2023 2023-05-11 F
SYY Sysco Corporation Q1 2023 2022-11-01 C+
GTES Gates Industrial Corporation plc Q4 2021 2022-02-07 C+
ESRT Empire State Realty Trust, Inc. Q2 2021 2021-07-29 C+

How the model reasoned

HCKT · Q1 2024 → YESThe question is about whether management describes one identifiable offering that's still small, where customer response is ahead of what they prepared for, AND they're responding now by putting more ...YES The transcript describes AI Explorer (the GenAI assessment platform) as a small, early-stage offering (nominal Q1 revenue impact, part of broader GenAI pivot). Management states customer response is exceeding preparation: "over 175 demo meetings with many more scheduled... resulted in a number of new enterprise...
SYY · Q1 2023 → YESThe question is about whether management describes one identifiable offering or initiative that's still a smaller part of the business, where customer response is running ahead of what they prepared f...YES The transcript shows that Sysco Your Way is presented as a smaller, still-developing offering (described as part of the Recipe For Growth pillars, with its scale expected to grow each quarter and currently limited to specific neighborhoods and recent international rollouts like Toronto and Dublin).
PRPH · Q1 2023 → YESThe question asks if management describes one identifiable offering that's still a smaller part of the business, where customer response is running ahead of what they prepared for, AND they're respond...YES The lozenge manufacturing facility is the clearest match. It is explicitly described as “the least interesting business we’re developing” and still a smaller slice of overall results (COVID testing was the dominant revenue driver for the prior two years).

More from the question bank

Said-then-did: management reports back on itManagement is buying/committing capital at aManagement is re-underwriting a specific assEvent-dense runwaySecond engine igniting off the firstEveryday buyers, repeat needAll questions →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.